Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Total Current Liabilities (2020 - 2025)

Historic Total Current Liabilities for HCW Biologics (HCWB) over the last 6 years, with Q3 2025 value amounting to $26.9 million.

  • HCW Biologics' Total Current Liabilities fell 1065.46% to $26.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.9 million, marking a year-over-year decrease of 1065.46%. This contributed to the annual value of $29.6 million for FY2024, which is 23870.78% up from last year.
  • According to the latest figures from Q3 2025, HCW Biologics' Total Current Liabilities is $26.9 million, which was down 1065.46% from $26.8 million recorded in Q2 2025.
  • In the past 5 years, HCW Biologics' Total Current Liabilities registered a high of $30.1 million during Q3 2024, and its lowest value of $1.1 million during Q2 2022.
  • Over the past 5 years, HCW Biologics' median Total Current Liabilities value was $5.0 million (recorded in 2023), while the average stood at $12.1 million.
  • As far as peak fluctuations go, HCW Biologics' Total Current Liabilities tumbled by 7254.9% in 2022, and later skyrocketed by 45501.47% in 2024.
  • Quarter analysis of 5 years shows HCW Biologics' Total Current Liabilities stood at $2.3 million in 2021, then rose by 27.35% to $3.0 million in 2022, then soared by 195.88% to $8.7 million in 2023, then surged by 238.71% to $29.6 million in 2024, then decreased by 9.34% to $26.9 million in 2025.
  • Its Total Current Liabilities was $26.9 million in Q3 2025, compared to $26.8 million in Q2 2025 and $27.1 million in Q1 2025.